Published in Immunol Today on September 01, 1991
Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov (2010) 7.48
Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev (2003) 3.70
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm (2008) 2.94
Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release (2013) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond) (2010) 1.51
Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells. Nat Med (2003) 1.38
The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol (2007) 1.37
Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One (2010) 1.35
A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion. J Neuroinflammation (2013) 1.29
Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev (2007) 1.24
Microglia, Alzheimer's disease, and complement. Int J Alzheimers Dis (2012) 1.21
Dysregulated inflammatory response to Candida albicans in a C5-deficient mouse strain. Infect Immun (2004) 1.15
Solution structure of Compstatin, a potent complement inhibitor. Protein Sci (1998) 1.15
Required early complement activation in contact sensitivity with generation of local C5-dependent chemotactic activity, and late T cell interferon gamma: a possible initiating role of B cells. J Exp Med (1997) 1.14
Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol (2008) 1.11
The role of complement in ocular pathology. Semin Immunopathol (2008) 1.07
Properdin deficiency in a large Swiss family: identification of a stop codon in the properdin gene, and association of meningococcal disease with lack of the IgG2 allotype marker G2m(n). Clin Exp Immunol (1999) 1.00
Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv (2013) 0.99
Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. Am J Pathol (1999) 0.98
Rous-Whipple Award Lecture. Role of complement in lung inflammatory injury. Am J Pathol (1996) 0.97
Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut (1998) 0.96
Mapping surface accessibility of the C1r/C1s tetramer by chemical modification and mass spectrometry provides new insights into assembly of the human C1 complex. J Biol Chem (2010) 0.94
Hereditary C6 deficiency in a strain of PVG/c rats. Clin Exp Immunol (1994) 0.93
Overview of the main methods used to combine proteins with nanosystems: absorption, bioconjugation, and encapsulation. Int J Nanomedicine (2010) 0.92
670-nm light treatment reduces complement propagation following retinal degeneration. J Neuroinflammation (2012) 0.90
Epithelium related deposition of activated complement in Helicobacter pylori associated gastritis. Gut (1997) 0.90
Nociceptive sensitization by complement C5a and C3a in mouse. Pain (2009) 0.89
Increased local concentration of complement C5a contributes to incisional pain in mice. J Neuroinflammation (2011) 0.89
Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations. Pharm Res (2011) 0.88
Cardiac failure in C5-deficient A/J mice after Candida albicans infection. Infect Immun (2006) 0.88
Expression and modulation of C5a receptor (CD88) on skin dendritic cells. Chemotactic effect of C5a on skin migratory dendritic cells. Immunology (1996) 0.87
Detection of anaphylatoxin receptors on CD83+ dendritic cells derived from human skin. Immunology (2001) 0.87
Deposition of complement components on Streptococcus agalactiae in bovine milk in the absence of inflammation. Infect Immun (1995) 0.87
Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology (1996) 0.87
Decomplementation by cobra venom factor suppresses Yersinia-induced arthritis in rats. Infect Immun (1995) 0.86
Anti-gluten immune response following Toxoplasma gondii infection in mice. PLoS One (2012) 0.86
Activation of the classical pathway of complement by binding of bovine lactoferrin to unencapsulated Streptococcus agalactiae. Immunology (1993) 0.85
Up-regulation of C5a receptor expression and function on human monocyte derived dendritic cells by prostaglandin E2. Immunology (2003) 0.84
Flavoxobin, a serine protease from Trimeresurus flavoviridis (habu snake) venom, independently cleaves Arg726-Ser727 of human C3 and acts as a novel, heterologous C3 convertase. Immunology (2002) 0.83
Genetic regulation of microglia activation, complement expression, and neurodegeneration in a rat model of traumatic brain injury. Exp Brain Res (2010) 0.83
Antimicrobial peptides and complement in neonatal hypoxia-ischemia induced brain damage. Front Immunol (2015) 0.83
The impact of PEGylation patterns on the in vivo biodistribution of mixed shell micelles. Int J Nanomedicine (2013) 0.81
Molecular determinants of the substrate specificity of the complement-initiating protease, C1r. J Biol Chem (2013) 0.81
Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability. Biochem J (1992) 0.81
The Immunology of Mammary Gland of Dairy Ruminants between Healthy and Inflammatory Conditions. J Vet Med (2014) 0.81
Regulation of complement C3 and C4 synthesis in human peritoneal mesothelial cells by peritoneal dialysis fluid. Clin Exp Immunol (2004) 0.80
Regulation of host cell transcriptional physiology by the avian pneumovirus provides key insights into host-pathogen interactions. J Virol (2003) 0.80
High complement factor I activity in the plasma of children with autism spectrum disorders. Autism Res Treat (2011) 0.80
Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction. Virchows Arch (1997) 0.79
Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clin Exp Immunol (2014) 0.78
Incubation Environment Affects Immune System Development in a Turtle with Environmental Sex Determination. J Herpetol (2008) 0.78
Social isolation disrupts innate immune responses in both male and female prairie voles and enhances agonistic behavior in female prairie voles (Microtus ochrogaster). Horm Behav (2015) 0.78
Complement component 3 inhibition by an antioxidant is neuroprotective after cerebral ischemia and reperfusion in mice. J Neurochem (2012) 0.77
Triggering of respiratory burst by phagocytosis in monocytes of patients with systemic lupus erythematosus. Clin Exp Immunol (1993) 0.77
Diminished adherence and/or ingestion of virulent Mycobacterium tuberculosis by monocyte-derived macrophages from patients with tuberculosis. Clin Diagn Lab Immunol (1998) 0.76
Complement component 3 (C3) expression in the hippocampus after excitotoxic injury: role of C/EBPβ. J Neuroinflammation (2016) 0.75
Mild hypothermia inhibits systemic and cerebral complement activation in a swine model of cardiac arrest. J Cereb Blood Flow Metab (2015) 0.75
Biological activities of C3 beta c, a novel neutrophil chemoattractant derived from the beta-chain of rat complement C3. Immunology (1998) 0.75
Multicolor cytoenzymatic evaluation of dipeptidyl peptidase IV (CD26) function in normal and neoplastic human T-lymphocyte populations. Clin Diagn Lab Immunol (1998) 0.75
CCAAT/enhancer binding protein β directly regulates the expression of the complement component 3 gene in neural cells: implications for the pro-inflammatory effects of this transcription factor. J Neuroinflammation (2015) 0.75
Downregulation of constitutive and cytokine-induced complement 3 expression by morphine in rat astrocytes. Curr Ther Res Clin Exp (2011) 0.75
Preparation of intravenous stealthy acyclovir nanoparticles with increased mean residence time. AAPS PharmSciTech (2009) 0.75
Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiency. Int J Nanomedicine (2015) 0.75
Blood histamine levels (BHL) in infants and children with respiratory and non-respiratory diseases. Mediators Inflamm (2001) 0.75
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol (1992) 2.50
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2. Microb Pathog (1987) 2.15
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
Comparison of live attenuated cold-adapted and avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccines in infants and children. J Infect Dis (1990) 1.40
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. J Infect Dis (1991) 1.28
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest (1989) 1.25
C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2. J Virol (1988) 1.14
Effect of heterosubtypic immunity on infection with attenuated influenza A virus vaccines in young children. J Clin Microbiol (1993) 1.14
IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med (1985) 1.11
High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood (1989) 1.06
Inheritance of mixed cryoglobulinemia. Am J Hum Genet (1981) 1.06
High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood (1991) 1.02
A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose. J Immunol Methods (1989) 0.99
The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol (1992) 0.97
Monocyte receptors for the Fc portion of IgG are increased in systemic lupus erythematosus. J Immunol (1984) 0.95
Monocyte receptors for the Fc portion of IgG increase in number in autoimmune hemolytic anemia and other hemolytic states and are decreased by glucocorticoid therapy. J Immunol (1983) 0.93
Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J (1995) 0.93
Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. J Allergy Clin Immunol (1988) 0.89
Factor I co-factor activity of CR1 overcomes the protective effect of IgG on covalently bound C3b residues. J Immunol (1985) 0.89
Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. Virology (1988) 0.89
Reduced infectivity of cold-adapted influenza A H1N1 viruses in the elderly: correlation with serum and local antibodies. J Am Geriatr Soc (1992) 0.88
In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol (1991) 0.88
High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood (1991) 0.87
Complement abnormalities in multiple myeloma. Am J Med (1989) 0.86
Monokines released during short-term Fc gamma receptor phagocytosis up-regulate polymorphonuclear leukocytes and monocyte-phagocytic function. J Immunol (1991) 0.85
Inherited deficiencies of complement and complement-related proteins. Clin Immunol Immunopathol (1986) 0.81
Accuracy of screening for pulmonary embolism in the emergency room. Respiration (1979) 0.81
CR1-receptor recycling in phorbol ester-activated polymorphonuclear leucocytes. Immunology (1988) 0.78
Studies of antibody and complement function in host defense against bacterial infection. Immunol Lett (1987) 0.77
Cunninghamella bertholletiae infection associated with deferoxamine therapy. Rev Infect Dis (1989) 0.77
Decline in rates of clearance of IgG-sensitized erythrocytes with increasing age. Blood (1988) 0.76
Interactions of monomeric IgG bearing covalently bound C3b with polymorphonuclear leucocytes. Immunology (1987) 0.75
Pre-ligation of CR1 enhances IgG-dependent phagocytosis by cultured human monocytes. J Immunol (1991) 0.75